Christopher R. Fenimore, EVP Finance and CFO of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), filed a Form 4 on November 4, 2026, disclosing multiple transactions in Regeneron common stock dated November 2, 2026.

Key Highlights

  • Option exercise: Fenimore exercised 6,000 Non-Qualified Stock Options at a conversion price of $381.92 per share on November 2, 2026, acquiring 6,000 shares of common stock (transaction code M).
  • Tax withholding disposition: 4,243 shares were disposed of at $950.50 per share on November 2, 2026, via transaction code F (shares withheld for taxes).
  • Gift transaction: 15 shares were disposed of at $0.00 on November 2, 2026, under transaction code G.
  • Direct ownership after transactions: Fenimore directly holds 21,726 shares of common stock following the reported transactions.
  • Indirect holdings: An additional 1,576 shares are held via a 401(k) Plan, 1,897 shares through a trust for the benefit of his spouse, and 25 shares each through separate trusts for a daughter and a son.
  • Options extinguished: The exercised options had an expiration date of December 16, 2026, and following the exercise, Fenimore holds 0 of those Non-Qualified Stock Options.

Fenimore's November 2026 Option Exercise and Share Transactions at Regeneron

According to the filing, Christopher R. Fenimore, identified as EVP Finance CFO of Regeneron Pharmaceuticals, Inc., exercised 6,000 Non-Qualified Stock Options on November 2, 2026, at an exercise price of $381.92 per share, acquiring 6,000 shares of common stock. The filing notes that the option award "vested in four equal annual installments, commencing one year after the date of grant," and those options carried an expiration date of December 16, 2026. Following the exercise, the filing reports Fenimore holds 0 of these options.

On the same date, the filing discloses that 4,243 shares were disposed of at a price of $950.50 per share under transaction code F, which typically denotes shares surrendered to the issuer to satisfy a tax withholding obligation. Additionally, 15 shares were disposed of at $0.00 under transaction code G, indicating a gift. After these transactions, Fenimore's direct beneficial ownership stood at 21,726 shares, according to the filing.

The filing also reports indirect holdings: 1,576 shares held through a 401(k) Plan; 1,897 shares held through a trust for the benefit of his spouse, of which the filing states Fenimore and his spouse serve as co-trustees; and 25 shares each held through a separate trust for a daughter and a trust for a son. The form was signed by Christopher R. Fenimore and dated November 4, 2026.

What Was Disclosed

Regeneron CFO Christopher R. Fenimore reported the exercise of 6,000 stock options at $381.92, the disposition of 4,243 shares at $950.50 (code F), and a gift of 15 shares on November 2, 2026, leaving him with 21,726 shares held directly.